首页> 外文期刊>Journal of cataract and refractive surgery >Phacoemulsification, primary posterior capsulorhexis, and capsular intraocular lens implantation for uveitic cataract.
【24h】

Phacoemulsification, primary posterior capsulorhexis, and capsular intraocular lens implantation for uveitic cataract.

机译:超声乳化,原发性后囊撕囊和葡萄膜白内障的人工晶状体囊内植入术。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: To evaluate the safety and efficacy of phacoemulsification, primary posterior capsulorhexis (PCCC), and primary intraocular lens (IOL) implantation for uveitic cataracts. SETTING: Institutional practice. METHODS: Fifteen consecutive eyes of 13 patients with various causes of uveitis received anterior capsulorhexis, phacoemulsification, PCCC, and in-the-bag implantation of a heparin-surface-modified IOL for visually disabling cataract. The safety and efficacy of the combined operation were studied prospectively. RESULTS: At a mean follow-up of 16.9 months (range 8 to 30 months), all eyes had a clear central visual area. Fourteen of 15 eyes (93.3%) had good visual improvement after surgery. Eight eyes (53%) achieved a best corrected visual acuity (BCVA) of 20/30 or better and 6 (40%), 20/20 or better. Seventy-three percent of eyes attained a BCVA of 20/80 or better. The mean improvement in visual acuity was 5.2 Snellen lines (range 0 to 11 lines). No cases of uveitis flare-up or other major complications related to the cataract surgery occurred. CONCLUSIONS: The study's preliminary results are encouraging and indicate that phacoemulsification, PCCC, and IOL implantation can be considered in patients with visually disabling uveitic cataract.
机译:目的:评估超声乳化术,原发性后囊撕脱术(PCCC)和原发性人工晶状体(IOL)植入术对葡萄膜性白内障的安全性和有效性。地点:机构实践。方法:13例因各种原因引起的葡萄膜炎的患者的十五只连续眼睛接受了前囊撕脱术,超声乳化术,PCCC以及囊内植入的肝素表面修饰的人工晶状体以治疗视力丧失的白内障。前瞻性研究了联合手术的安全性和有效性。结果:平均随访16.9个月(范围8到30个月),所有眼睛均具有清晰的中央视觉区域。手术后15只眼睛中有14只(93.3%)的视觉改善良好。八只眼(53%)的最佳矫正视力(BCVA)为20/30或更高,而六只(40%)为20/20或更高。 73%的眼睛的BCVA达到20/80或更高。视力的平均改善为5.2 Snellen线(范围为0至11线)。没有发生与白内障手术有关的葡萄膜炎发作或其他主要并发症。结论:该研究的初步结果令人鼓舞,表明对于视力丧失的葡萄膜白内障患者,可以考虑超声乳化,PCCC和人工晶体植入。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号